Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D07TRP
|
|||
Former ID |
DIB016351
|
|||
Drug Name |
APTO-253
|
|||
Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-9: 140-199, 210-229] | Phase 1 | [1] | |
Company |
Aptose biosciences
|
|||
Structure |
Download2D MOL |
|||
Formula |
C22H14FN5
|
|||
Canonical SMILES |
CC1=C(C2=C(N1)C=CC(=C2)F)C3=NC4=C5C=CC=NC5=C6C(=C4N3)C=CC=N6
|
|||
InChI |
1S/C22H14FN5/c1-11-17(15-10-12(23)6-7-16(15)26-11)22-27-20-13-4-2-8-24-18(13)19-14(21(20)28-22)5-3-9-25-19/h2-10,26H,1H3,(H,27,28)
|
|||
InChIKey |
NIRXBXIPHUTNNI-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 916151-99-0
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Kruppel like factor 4 (KLF4) | Target Info | Inhibitor | [2] |
KEGG Pathway | Signaling pathways regulating pluripotency of stem cells | |||
Pathway Interaction Database | Regulation of nuclear beta catenin signaling and target gene transcription | |||
Reactome | Transcriptional regulation of white adipocyte differentiation | |||
Transcriptional regulation of pluripotent stem cells | ||||
WikiPathways | Vitamin D Receptor Pathway | |||
Mesodermal Commitment Pathway | ||||
Transcriptional regulation of pluripotent stem cells | ||||
Transcriptional Regulation of White Adipocyte Differentiation | ||||
Cell Differentiation - meta | ||||
SRF and miRs in Smooth Muscle Differentiation and Proliferation | ||||
Synthesis, Secretion, and Deacylation of Ghrelin |
References | Top | |||
---|---|---|---|---|
REF 1 | ClinicalTrials.gov (NCT02267863) A Study of APTO-253 HCl in Patients With Relapsed or Refractory Hematologic Malignancies. U.S. National Institutes of Health. | |||
REF 2 | Phase 1 study of APTO-253 HCl, an inducer of KLF4, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2015 Oct;33(5):1086-92. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.